var data={"title":"Cyclosporine (ciclosporin) (systemic): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cyclosporine (ciclosporin) (systemic): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/388095?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cyclosporine (ciclosporin) (systemic): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cyclosporine (ciclosporin) (systemic): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012536\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Only health care providers experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe cyclosporine. At doses used in solid organ transplantation, only health care providers experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe cyclosporine. Patients receiving cyclosporine should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The health care provider responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Immunosuppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients, Gengraf and Neoral may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Sandimmune and cyclosporine injection should be administered with adrenal corticosteroids but not with other immunosuppressive agents.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bioavailability:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The absorption of Sandimmune capsules and oral solution during long-term administration was found to be erratic. It is recommended that patients taking Sandimmune capsules or oral solution over a period of time be monitored at repeated intervals for cyclosporine blood levels and that subsequent dose adjustments be made to avoid toxicity from high levels and possible organ rejection from low absorption of cyclosporine. This is of special importance in liver transplants. Numerous assays are being developed to measure blood levels of cyclosporine.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Sandimmune capsules and oral solution have decreased bioavailability in comparison with Gengraf and Neoral capsules and Gengraf and Neoral oral solution. Gengraf and Neoral have increased bioavailability compared to Sandimmune capsules and oral solution and are not bioequivalent to Sandimmune and cannot be used interchangeably without the supervision of a health care provider. For a given trough concentration, cyclosporine exposure will be greater with Neoral and Gengraf than with Sandimmune. If a patient who is receiving exceptionally high doses of Sandimmune is converted to Neoral or Gengraf, particular caution should be exercised. Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis (RA) patients taking Gengraf and Neoral to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Psoriasis (Neoral, Gengraf):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Psoriasis patients previously treated with psoralens plus ultraviolet A (PUVA) and, to a lesser extent, methotrexate or other immunosuppressive agents, ultraviolet B (UVB), coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking cyclosporine. Also see boxed warnings above.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypertension/nephrotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine, in recommended doses, can cause systemic hypertension and nephrotoxicity. The risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine and, therefore, renal function must be monitored during therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012539\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Gengraf;</li>\n      <li>Neoral;</li>\n      <li>SandIMMUNE</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012540\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Cyclosporine;</li>\n      <li>Neoral;</li>\n      <li>Sandimmune I.V.;</li>\n      <li>Sandoz-Cyclosporine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8015573\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Calcineurin Inhibitor;</li>\n      <li>\n        Immunosuppressant Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012583\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Neoral/Gengraf (cyclosporine modified) and Sandimmune (cyclosporine non-modified) are not bioequivalent and cannot be used interchangeably. Use caution when selecting, dispensing, and administrating cyclosporine products; in general, cyclosporine (modified) is more commonly used clinically.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriasis:</b> Oral: Cyclosporine (modified): Initial dose: 2.5 mg/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Titration:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Increase by 0.5 mg/kg/day if insufficient response is seen after 4 weeks of treatment. Additional dosage increases may be made every 2 weeks if needed (maximum dose: 4 mg/kg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Guideline recommended dosing: </i>2.5 to 5 mg/kg/day in 2 divided doses, adjust dose downward in 0.5 to 1 mg/kg increments when clearance of psoriasis is achieved or if hypertension or decreased renal function occur; interval therapy is preferred (Menter 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Discontinue if no benefit is seen by 6 weeks of therapy at the maximum dose. Once patients are adequately controlled, the dose should be decreased to the lowest effective dose. Doses lower than 2.5 mg/kg/day may be effective. Treatment longer than 1 year is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Cyclosporine dosage should be decreased by 25% to 50% in patients with no history of hypertension who develop sustained hypertension during therapy and, if hypertension persists, treatment with cyclosporine should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Oral: Cyclosporine (modified): Initial dose: 2.5 mg/kg/day in 2 divided doses; salicylates, NSAIDs, and oral glucocorticoids may be continued (refer to Drug Interactions)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Titration: Dose may be increased by 0.5 to 0.75 mg/kg/day if insufficient response is seen after 8 weeks of treatment; additional dosage increases may be made again at 12 weeks (maximum dose: 4 mg/kg daily). Discontinue if no benefit is seen by 16 weeks of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Cyclosporine dosage should be decreased by 25% to 50% in patients with no history of hypertension who develop sustained hypertension during therapy and, if hypertension persists, treatment with cyclosporine should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Solid organ transplant (newly transplanted patients):</b> Cyclosporine is commonly used in combination with an antiproliferative immunosuppressive agent and a corticosteroid. Although cyclosporine may be initiated preoperatively, it is more frequently started postoperatively (depending on concomitant renal function); adjust dose to achieve desired plasma concentration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Dose is dependent upon type of transplant and formulation; refer to institutional protocol for specific dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cyclosporine (modified): Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Renal: 9 &plusmn; 3 mg/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Liver: 8 &plusmn; 4 mg/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Heart: 7 &plusmn; 3 mg/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cyclosporine (non-modified): Refer to institutional protocol for specific dosing; dosing in clinical practice may differ greatly compared to the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> When using the non-modified formulation, cyclosporine levels may increase in liver transplant patients when the T-tube is closed; dose may need decreased</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Cyclosporine (non-modified): Manufacturer's labeling: Initial dose: 5 to 6 mg/kg/day or one-third of the oral dose as a single dose, infused over 2 to 6 hours; use should be limited to patients unable to take capsules or oral solution; patients should be switched to an oral dosage form as soon as possible.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Many transplant centers administer cyclosporine as &quot;divided dose&quot; infusions (in 2 doses daily) or as a continuous (24-hour) infusion; dosages range from 3 to 7.5 mg/kg/day. Specific institutional protocols should be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: Conversion to cyclosporine (modified) from cyclosporine (non-modified):</b> Start with daily dose previously used and adjust to obtain preconversion cyclosporine trough concentration. Plasma concentrations should be monitored every 4 to 7 days and dose adjusted as necessary, until desired trough level is obtained. When transferring patients with previously poor absorption of cyclosporine (non-modified), monitor trough levels at least twice weekly (especially if initial dose exceeds 10 mg/kg daily); high plasma levels are likely to occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute graft versus host disease (aGVHD), prevention (off-label use): </b> IV followed by oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: IV: 3 mg/kg/day 1 day prior to transplant; may convert to oral therapy when tolerated; titrate dose to appropriate cyclosporine trough concentration (in combination with methotrexate); taper per protocol (refer to specific references and institutional protocols for tapering and target trough details); discontinue 6 months post-transplant in the absence of acute GVHD (Ratanatharathorn 1998; Ruutu 2014; Storb 1986a; Storb 1986b)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: IV: 5 mg/kg/day (as a continuous infusion over 20 hours) for 6 days (loading dose) starting 2 days prior to transplant, then 3 mg/kg/day over 20 hours for 11 days starting on post-transplant day 4, then 3.75 mg/kg/day over 20 hours for 21 days starting on day 15, then <b>oral </b>(in 2 divided daily doses): 10 mg/kg/day days 36 to 83, then 8 mg/kg/day days 84 to 97, then 6 mg/kg/day days 98 to 119, then 4 mg/kg/day days 120 to 180, then discontinue (in combination with methotrexate +/- corticosteroid) (Chao 1993; Chao 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Focal segmental glomerulosclerosis (off-label use):</b> Oral: Initial: 3.5 to 5 mg/kg/day in 2 divided doses (every 12 hours; in combination with oral prednisone) (Braun 2008; Cattran 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immune thrombocytopenia, refractory (off-label use): </b>Oral: 5 mg/kg/day in 2 divided doses (every 12 hours) for 6 days, followed by 2.5 to 3 mg/kg/day (titrate to serum levels of 100 to 200 ng/mL); time to response in clinical trials was ~3 to 4 weeks (Provan 2010). Additional studies have used initial doses of 2.5 to 5 mg/kg/day in 2 divided doses; maintenance doses were adjusted to maintain serum levels between 150 and 400 ng/mL (Choudhary 2008; Emilia 2002; Zver 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Interstitial cystitis (bladder pain syndrome) (off-label use):</b> Oral: Initial: 2 to 3 mg/kg/day in 2 divided doses (maximum of 300 mg daily). Once symptom relief is established, the dose can be tapered as tolerated (to as low as 1 mg/kg as a single daily dose) and in some cases can be stopped with continued benefit. Treatment duration was at least 6 months to more than 1 year in some patients (Forrest 2012; Sairanen 2004; Sairanen 2005; Sairanen 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung transplant (prevention of acute rejection) (off-label use)</b>: IV followed by oral: Initial: 1 mg/kg/day IV beginning immediately after transplantation (in combination with other transplant immunosuppressants); convert to oral cyclosporine as soon as possible post extubation. Target cyclosporine levels were maintained between 250 and 350 ng/mL during the first month, and around 200 ng/mL thereafter (Zuckermann 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nephrotic syndrome</b> <i>(Canadian labeling):</i> Oral: Cyclosporine (modified):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial: 3.5 mg/kg/day in 2 divided doses (every 12 hours); titrate for induction of remission and renal function. Adjunct therapy with low-dose oral corticosteroids is recommended for patients with an inadequate response to cyclosporine (particularly if steroid-resistant).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maintenance: Dose is individualized based on proteinuria, serum creatinine, and tolerability but should be maintained at lowest effective dose; maximum dose: 5 mg/kg daily. Discontinue if no improvement is observed after 3 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lupus nephritis (off-label use):</b> Oral: Cyclosporine (modified): Initial: 4 mg/kg/day for 1 month (reduce dose if trough concentrations &gt;200 ng/mL); reduce dose by 0.5 mg/kg every 2 weeks to a maintenance dose of 2.5 to 3 mg/kg/day (Moroni 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis, severe (steroid-refractory) (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Cyclosporine (non-modified): 2 to 4 mg/kg/day, infused continuously over 24 hours. (Lichtiger 1994; Van Assche 2003). <b>Note:</b> Some studies suggest no therapeutic difference between low-dose (2 mg/kg) and high-dose (4 mg/kg) cyclosporine regimens (Van Assche 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Cyclosporine (modified): 2.3 to 3 mg/kg every 12 hours (De Saussure 2005; Weber 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Patients responsive to IV therapy should be switched to oral therapy when possible.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uveitis (off-label dose): </b>Oral: 2.5 to 5 mg/kg/day in 2 divided doses; gradually decrease to maintenance dose; used alone or in conjunction with other corticosteroids (Isnard Bagnis 2002; Matthews 2010; Murphy 2005; Ozdal 2002; Zaghetto 2010). An expert panel recommends initial dose of 3 to 5 mg/kg/day; reducing dose, once inflammation was under control, to 2 to 3 mg/kg/day until a maintenance dose of 1 mg/kg/day is achieved (Diaz-Llopis 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012582\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Cyclosporine (ciclosporin) (systemic): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Neoral/Gengraf (cyclosporine modified) and Sandimmune (cyclosporine non-modified) are not bioequivalent and cannot be used interchangeably. Use caution when selecting, dispensing, and administrating cyclosporine products; in general, cyclosporine (modified) is more commonly used clinically.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute graft versus host disease (aGVHD), prevention (off-label use): </b>Infants, Children, and Adolescents: IV followed by oral: Initial: 3 to 5 mg/kg/day in 2 divided doses (every 12 hours) administered over 2 hours or as a single daily dose administered over 8 hours (Lanino 2009; Martin 2003; Storb 1986a) or 3 mg/kg/day as a continuous infusion (Nash 2000) beginning one day prior to transplant; may be given with or without methotrexate. May convert to oral therapy when tolerating oral intake; titrate dose to appropriate cyclosporine trough concentration (reported doses ranged from 6 to 12.5 mg/kg/day in divided doses every 12 hours); taper per protocol (refer to specific references for tapering and target trough details). Discontinue 6 months post-transplant in the absence of acute GVHD; refer to specific references for discontinuation details (Lanino 2009; Martin 2003; Storb 1986a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nephrotic syndrome (off-label use):</b> Children and Adolescents: Oral: Initial: 4 to 5 mg/kg/day in 2 divided doses for at least 12 months <b>or</b> 150 mg/m<sup>2</sup>/day in 2 divided doses; adjust doses based on trough levels (Gellermann 2013; KDIGO 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Solid organ transplant:</b> Refer to adult dosing. Children may require, and are able to tolerate, higher doses than adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012644\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012645\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriasis (severe):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Abnormal renal function prior to treatment: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Abnormal renal function during treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine levels &ge;25% above pretreatment levels: Take another sample within 2 weeks; if the level remains &ge;25% above pretreatment levels, decrease dosage of cyclosporine (modified) by 25% to 50%. If two dosage adjustments do not reverse the increase in serum creatinine levels, treatment should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum creatinine levels &ge;50% above pretreatment levels: Decrease cyclosporine dosage by 25% to 50%. If two dosage adjustments do not reverse the increase in serum creatinine levels, treatment should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Abnormal renal function prior to treatment: Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Abnormal renal function during treatment: Serum creatinine levels &gt;30% above pretreatment levels: Decrease cyclosporine dosage by 25% to 50%; discontinue if dose reduction is ineffective in controlling serum creatinine elevation or if serum creatinine is severe.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nephrotic syndrome: </b>\n      <i>Canadian labeling:</i> Initial: 2.5 mg/kg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Serum creatinine levels &gt;30% above pretreatment levels: Take another sample within 2 weeks; if the level remains &gt;30% above pretreatment levels, decrease dosage of cyclosporine (modified) by 25% to 50%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: Adults: Supplemental dose is not necessary (Aronoff 2007). Dialysis does not significantly alter cyclosporine clearance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: Adults: Supplemental dose is not necessary (Aronoff 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012646\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Mild-to-moderate impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; monitor blood concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, metabolism is extensively hepatic (exposure is increased). Monitor blood concentrations; may require dose reduction.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012692\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf: 25 mg [contains cremophor el, fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf: 50 mg [contains alcohol, usp, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf: 100 mg [contains cremophor el, fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neoral: 25 mg, 100 mg [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandIMMUNE: 25 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandIMMUNE: 50 mg/mL (5 mL) [contains alcohol, usp, cremophor el]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/mL (5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf: 100 mg/mL (50 mL) [contains propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neoral: 100 mg/mL (50 mL) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandIMMUNE: 100 mg/mL (50 mL) [contains alcohol, usp]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/mL (50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012552\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21664250\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine (modified): Gengraf and Neoral</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine (non-modified): SandIMMUNE</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclosporine injection contains polyoxyethylated castor oil (Cremophor EL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23294978\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:0em;\">Capsule, Oral:</p>\n    <p style=\"text-indent:2em;\">Neoral: 10 mg, 25 mg, 50 mg, 100 mg [contains alcohol]</p>\n    <p style=\"text-indent:0em;\">Solution, Intravenous:</p>\n    <p style=\"text-indent:2em;\">SandIMMUNE IV: 50 mg/mL (1 mL, 5 mL) [contains alcohol, cremophor el]</p>\n    <p style=\"text-indent:0em;\">Solution, Oral:</p>\n    <p style=\"text-indent:2em;\">Neoral: 100 mg/mL (50 mL) [contains alcohol, propylene glycol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012649\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Do not administer liquid from plastic or styrofoam cup. May dilute Neoral oral solution with room temperature orange juice or apple juice. May dilute Sandimmune oral solution with milk, chocolate milk, or orange juice. Avoid changing diluents frequently. Mix thoroughly and drink at once. Use syringe provided to measure dose. Mix in a glass container and rinse container with more diluent to ensure total dose is taken. Do not rinse syringe before or after use (may cause dose variation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Administer this medication consistently with relation to time of day and meals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Combination therapy with renal or heart transplantation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Everolimus: May administer cyclosporine at the same time as everolimus</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sirolimus: Must administer cyclosporine 4 hours separate from sirolimus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: The manufacturer recommends that following dilution, intravenous admixture be administered over 2 to 6 hours. However, many transplant centers administer as divided doses (2 doses/day) or as a 24-hour continuous infusion. Anaphylaxis has been reported with IV use; reserve for patients who cannot take oral form. Patients should be under continuous observation for at least the first 30 minutes of the infusion, and should be monitored frequently thereafter. Maintain patent airway; other supportive measures and agents for treating anaphylaxis should be present when IV drug is given. To minimize leaching of DEHP, non-PVC sets should be used for administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130962\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, when compounding, double gloves, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) are recommended. Double gloving and a gown are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012553\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cyclosporine modified:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplant rejection prophylaxis: </b>Prophylaxis of organ rejection in kidney, liver, and heart transplants (commonly used in combination with an antiproliferative immunosuppressive agent and corticosteroid).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b> Treatment of severe, active rheumatoid arthritis (RA) not responsive to methotrexate alone</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriasis:</b> Treatment of severe, recalcitrant plaque psoriasis in non-immunocompromised adults unresponsive to or unable to tolerate other systemic therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cyclosporine non-modified: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplant rejection (prophylaxis):</b> Prophylaxis of organ rejection in kidney, liver, and heart transplants (commonly used in combination with an antiproliferative agent and a corticosteroid)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Transplant rejection, chronic (treatment):</b> May be used for the treatment of chronic rejection (kidney, liver, and heart) in patients previously treated with other immunosuppressive agents. <b>Note:</b> While approved for the treatment of chronic organ rejection, other therapies are clinically preferred in this setting.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475238\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute graft-versus-host disease (prophylaxis) (adults); Acute graft-versus-host disease (prophylaxis) (pediatrics); Chronic graft-versus-host disease (treatment); Focal segmental glomerulosclerosis; Immune thrombocytopenia, refractory (adults); Interstitial cystitis (bladder pain syndrome); Lung transplant (prevention of acute rejection); Lupus nephritis; Nephrotic syndrome (pediatrics); Psoriasis (pediatrics); Ulcerative colitis, severe refractory; Uveitis (adults); Juvenile idiopathic arthritis (refractory)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012538\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CycloSPORINE may be confused with cyclophosphamide, Cyklokapron, cycloSERINE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CycloSPORINE modified (Neoral, Gengraf) may be confused with cycloSPORINE non-modified (SandIMMUNE)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gengraf may be confused with Prograf</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neoral may be confused with Neurontin, Nizoral</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SandIMMUNE may be confused with SandoSTATIN</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012602\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions reported with systemic use, including rheumatoid arthritis, psoriasis, and transplantation (kidney, liver, and heart). Percentages noted include the highest frequency regardless of indication/dosage. Frequencies may vary for specific conditions or formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension (8% to 53%), edema (5% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (2% to 25%), paresthesia (1% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Hypertrichosis (5% to 19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hirsutism (21% to 45%), increased serum triglycerides (15%), female genital tract disease (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (2% to 23%), diarrhea (3% to 13%), gingival hyperplasia (2% to 16%), abdominal distress (&lt;1% to 15%), dyspepsia (2% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary tract infection (kidney transplant: 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Increased susceptibility to infection (3% to 25%), viral infection (kidney transplant: 16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Tremor (7% to 55%), leg cramps (2% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine (16% to &ge;50%), renal insufficiency (10% to 38%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Upper respiratory tract infection (1% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Kidney, liver, and heart transplant only (&le;2% unless otherwise noted):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain (&le;4%), flushing (&lt;1% to 4%), glomerular capillary thrombosis, myocardial infarction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Convulsions (1% to 5%), anxiety, confusion, lethargy, tingling sensation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin infection (7%), acne vulgaris (1% to 6%), nail disease (brittle fingernails), hair breakage, night sweats, pruritus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Gynecomastia (&lt;1% to 4%), hyperglycemia, hypomagnesemia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Vomiting (2% to 10%), anorexia, aphthous stomatitis, constipation, dysphagia, gastritis, hiccups, pancreatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Leukopenia (&lt;1% to 6%), lymphoma (&lt;1% to 6%), anemia, thrombocytopenia, upper gastrointestinal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hepatotoxicity (&lt;1% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Localized fungal infection (8%), cytomegalovirus disease (5%), septicemia (5%), abscess (4%), fungal infection (systemic: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Conjunctivitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Hearing loss, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Sinusitis (&lt;1% to 7%), pneumonia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Rheumatoid arthritis only (1% to &lt;3% unless otherwise noted):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain (4%), cardiac arrhythmia (2%), abnormal heart sounds, cardiac failure, myocardial infarction, peripheral ischemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (8%), pain (6%), insomnia (4%), depression (3%), migraine (2% to 3%), anxiety, drowsiness, emotional lability, hypoesthesia, lack of concentration, malaise, neuropathy, nervousness, paranoia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Cellulitis, dermatological reaction, dermatitis, diaphoresis, dyschromia, eczema, enanthema, folliculitis, nail disease, pruritus, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Menstrual disease (3%), decreased libido, diabetes mellitus, goiter, hot flash, hyperkalemia, hyperuricemia, hypoglycemia, increased libido, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Vomiting (9%), flatulence (5%), gingivitis (4%), constipation, dysgeusia, dysphagia, enlargement of salivary glands, eructation, esophagitis, gastric ulcer, gastritis, gastroenteritis, gingival hemorrhage, glossitis, peptic ulcer, tongue disease, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Leukorrhea (1%), breast fibroadenosis, hematuria, mastalgia, nocturia, urine abnormality, urinary incontinence, urinary urgency, uterine hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Purpura (3% to 4%), anemia, carcinoma, leukopenia, lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Abscess (including renal), bacterial infection, candidiasis, fungal infection, herpes simplex infection, herpes zoster, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, bone fracture, dislocation, myalgia, stiffness, synovial cyst, tendon disease, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Cataract, conjunctivitis, eye pain, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Tinnitus, deafness, vestibular disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Abscess (renal), increased blood urea nitrogen, polyuria, pyelonephritis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (5%), dyspnea (5%), sinusitis (4%), abnormal breath sounds, bronchospasm, epistaxis, tonsillitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Psoriasis only (1% to &lt;3% unless otherwise noted):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest pain, flushing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Psychiatric disturbance (4% to 5%), pain (3% to 4%), dizziness, insomnia, nervousness, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Acne vulgaris, folliculitis, hyperkeratosis, pruritus, skin rash, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal distention, constipation, gingival hemorrhage, increased appetite</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary frequency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Abnormal erythrocytes, altered platelet function, blood coagulation disorder, carcinoma, hemorrhagic diathesis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (1% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Flu-like symptoms (8% to 10%), bronchospasm (5%), cough (5%), dyspnea (5%), rhinitis (5%), respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Postmarketing and/or case reports (any indication):</b> Anaphylaxis/anaphylactoid reaction (possibly associated with Cremophor EL vehicle in injection formulation), brain disease, central nervous system toxicity, cholestasis, cholesterol increased, exacerbation of psoriasis (transformation to erythrodermic or pustular psoriasis), fatigue, gout, haemolytic uremic syndrome, hepatic insufficiency, hepatitis, hyperbilirubinemia, hyperkalemia, hyperlipidemia, hypertrichosis, hyperuricemia, hypomagnesemia, impaired consciousness, increased susceptibility to infection (including JC virus and BK virus), jaundice, leg pain (possibly a manifestation of Calcineurin-Inhibitor Induced Pain Syndrome), malignant lymphoma, migraine, myalgia, myopathy, myositis, papilledema, progressive multifocal leukoencephalopathy, pseudotumor cerebri, pulmonary edema (noncardiogenic), renal disease (polyoma virus-associated), reversible posterior leukoencephalopathy syndrome, rhabdomyolysis, thrombotic microangiopathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012561\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to cyclosporine or any component of the formulation. IV cyclosporine is contraindicated in hypersensitivity to polyoxyethylated castor oil (Cremophor EL).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rheumatoid arthritis and psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies. Concomitant treatment with PUVA or UVB therapy, methotrexate, other immunosuppressive agents, coal tar, or radiation therapy are also contraindications for use in patients with psoriasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Concurrent use with bosentan; rheumatoid arthritis and psoriasis patients with primary or secondary immunodeficiency excluding autoimmune disease, uncontrolled infection, or malignancy (excluding non-melanoma skin cancer).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012600\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gingival hyperplasia: Gingival hyperplasia may occur; avoid concomitant nifedipine in patients who develop gingival hyperplasia (may increase frequency of hyperplasia). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: Hepatotoxicity (transaminase and bilirubin elevations) and liver injury (including cholestasis, jaundice, hepatitis, and liver failure) have been reported. These events were mainly in patients with confounding factors including infections, coadministration with other potentially hepatotoxic medications, underlying conditions, and significant comorbidities. Fatalities have also been reported rarely, primarily in transplant patients. Increased hepatic enzymes and bilirubin have occurred, usually in the first month and when used at high doses; improvement is usually seen with dosage reduction. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperkalemia: Significant hyperkalemia, with or without hyperchloremic metabolic acidosis, has been reported. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertension:<b> [US Boxed Warning]: May cause hypertension; risk is increased with increasing doses/duration. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperuricemia: Significant hyperuricemia has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infections:<b> [US Boxed Warning]: Increased risk of infection with use; </b> fatal infections have been reported. Bacterial, viral, fungal, and protozoal infections (including opportunistic infections) have occurred. Polyoma virus infections, such as the JC virus and BK virus, may result in serious and sometimes fatal outcomes. The JC virus is associated with progressive multifocal leukoencephalopathy (PML), and PML has been reported in patients receiving cyclosporine. PML may be fatal and presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia; consider neurologic consultation as indicated. The BK virus is associated with nephropathy, and polyoma virus-associated nephropathy (PVAN) has been reported in patients receiving cyclosporine. PVAN is associated with serious adverse effects including renal dysfunction and renal graft loss. If PML or PVAN occur in transplant patients, consider reducing immunosuppression therapy as well as the risk  that reduced immunosuppression poses to grafts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Malignancy:<b> [US Boxed Warning]: Increased risk of lymphomas and other malignancies</b> (including fatal outcomes), <b>particularly skin cancers;</b> risk is related to intensity/duration of therapy and the use of more than one immunosuppressive agent; all patients should avoid excessive sun/UV light exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Nephrotoxicity: <b>[US Boxed Warning]: Renal impairment, including structural kidney damage has occurred (when used at high doses); risk is increased with increasing doses/duration; monitor renal function closely.</b> Use caution with other potentially nephrotoxic drugs (eg, acyclovir, aminoglycoside antibiotics, amphotericin B, ciprofloxacin); monitor renal function closely with concomitant use. If significant renal impairment occurs, reduce the dose of the coadministered medication or consider alternative treatment. Elevations in serum creatinine and BUN associated with nephrotoxicity generally respond to dosage reductions. In renal transplant patients with rapidly rising BUN and creatinine, carefully evaluate to differentiate between cyclosporine-associated nephrotoxicity and renal rejection episodes. In cases of severe rejection that fail to respond to pulse steroids and monoclonal antibodies, switching to an alternative immunosuppressant agent may be preferred to increasing cyclosporine to excessive blood concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: May cause seizures, particularly if used with high-dose corticosteroids. Encephalopathy (including posterior reversible encephalopathy syndrome [PRES]) has also been reported; predisposing factors include hypertension, hypomagnesemia, hypocholesterolemia, high-dose corticosteroids, high cyclosporine serum concentration, and graft-versus-host disease (GVHD). Encephalopathy may be more common in patients with liver transplant compared to kidney transplant. Other neurotoxic events, such as optic disc edema (including papilloedema and potential visual impairment), have been rarely reported primarily in transplant patients. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Skin cancer: <b>[US Boxed Warning]: Risk of skin cancer may be increased in psoriasis patients with a history of PUVA and possibly methotrexate or other immunosuppressants, UVB, coal tar, or radiation; </b> increased risk of skin cancer has also been established in transplant patients; risk is related to intensity/duration of therapy and the use of more than one immunosuppressive agent; all patients should avoid excessive sun/UV light exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thrombotic microangiopathy: In transplant patients, syndromes of microangiopathic hemolytic anemia and thrombocytopenia have occurred and may result in graft failure; it is accompanied by platelet consumption within the graft. Syndrome may occur without graft rejection. Although management of the syndrome is unclear, discontinuation or reduction of cyclosporine, in addition to streptokinase and heparin administration or plasmapheresis, has been associated with syndrome resolution. However, resolution seems to be dependent upon early detection of the syndrome via indium 111 labeled platelet scans.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Cyclosporine has extensive hepatic metabolism and exposure is increased in patients with severe hepatic impairment. May require dose reduction. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psoriasis: Appropriate use: If receiving other immunosuppressive agents, radiation or UV therapy, concurrent use of cyclosporine is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cyclosporine combination therapy in renal transplant: Due to the increased risk for nephrotoxicity in renal transplantation, avoid using standard doses of cyclosporine in combination with everolimus; reduced cyclosporine doses are recommended; monitor cyclosporine concentrations closely. Cyclosporine and everolimus combination therapy may increase the risk for proteinuria. Cyclosporine combined with either everolimus or sirolimus may increase the risk for thrombotic microangiopathy/thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TMA/TTP/HUS).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug/drug-food interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Transplant patients: To be used initially with corticosteroids. Make dose adjustments based on cyclosporine blood concentrations. Anaphylaxis has been reported with IV use; reserve for patients who cannot take oral form.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Corn oil: Product may contain corn oil.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ethanol: Products may contain ethanol. The alcohol content should be considered in certain patient populations, including pregnant or breast-feeding women, patients with liver disease, seizure disorders, alcohol dependency, or pediatric patients. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Non-interchangeability of modified/non-modified forms: <b>[US Boxed Warning]: The modified/non-modified formulations are not bioequivalent; cyclosporine (modified) has increased bioavailability as compared to cyclosporine (non-modified) and the products cannot be used interchangeably without close monitoring.</b> Cyclosporine (modified) refers to the oral solution and capsule dosage formulations of cyclosporine in an aqueous dispersion (previously referred to as &ldquo;microemulsion&rdquo;).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polyoxyethylated castor oil: Cyclosporine for injection contains the vehicle polyoxyethylated castor oil (Cremophor EL), which is associated with hypersensitivity (anaphylactic) reactions. Due to the risk for anaphylaxis, IV cyclosporine should be reserved for use in patients unable to take an oral formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[US Boxed Warning]: Prescribing and dosage adjustment should only be under the direct supervision of an experienced physician. Adequate laboratory/medical resources and follow-up are necessary. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Monitoring of concentrations: Monitor cyclosporine concentrations closely following the addition, modification, or deletion of other medications.  <b>[US Boxed Warning]: Cyclosporine non-modified absorption is erratic; monitor blood concentrations closely. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vaccines: Live, attenuated vaccines may be less effective; vaccination should be avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012607\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, BSEP/ABCB11, CYP2C9 (weak), CYP3A4 (weak), OATP1B1/SLCO1B1, P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012608\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9094&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AcetaZOLAMIDE: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adalimumab: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: CycloSPORINE (Systemic) may increase the serum concentration of Aliskiren. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ambrisentan: CycloSPORINE (Systemic) may increase the serum concentration of Ambrisentan.  Management: Limit ambrisentan dose to 5 mg/day and monitor for ambrisentan adverse reactions in patients receiving systemic cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May increase the serum concentration of CycloSPORINE (Systemic). Management: Monitor for increased serum concentrations and/or toxicity of cyclosporine if combined with amiodarone. A reduction in cyclosporine dosage will likely be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of CycloSPORINE (Systemic). Fluconazole and isavuconazonium considerations are addressed in separate monographs.<b> Exceptions: </b>Fluconazole; Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Armodafinil: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ascorbic Acid: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: CycloSPORINE (Systemic) may increase the serum concentration of AtorvaSTATin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azithromycin (Systemic): May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: CycloSPORINE (Systemic) may increase the serum concentration of Boceprevir. Boceprevir may increase the serum concentration of CycloSPORINE (Systemic).  Management: Cyclosporine dose adjustments will likely be necessary when used together with boceprevir.  Monitor serum cyclosporine concentrations closely, and monitor patients for evidence of cyclosporine toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CycloSPORINE (Systemic) may increase the serum concentration of Bosentan. Bosentan may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Dihydropyridine): May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).<b> Exceptions: </b>Clevidipine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Monitor frequently for decreased serum concentrations and therapeutic effects of cyclosporine if combined with carbamazepine. Increased cyclosporine doses will likely be needed to maintain adequate serum concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caspofungin: CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin.  Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity.  Monitor liver function and re-evaluate treatment in patients with abnormal values.  Mild transaminase elevations may occur relatively commonly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): May increase the serum concentration of CycloSPORINE (Systemic). Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholic Acid: BSEP/ABCB11 Inhibitors may decrease the excretion of Cholic Acid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colesevelam: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer cyclosporine at least 4 hours prior to colesevelam.  Monitor for decreased cyclosporine concentrations during concomitant colesevelam therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: May enhance the immunosuppressive effect of CycloSPORINE (Systemic). Cyclophosphamide may decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May decrease the serum concentration of CycloSPORINE (Systemic). Dexamethasone (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Dexamethasone (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: CycloSPORINE (Systemic) may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CycloSPORINE (Systemic) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Consider a doxorubicin dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution; increase monitoring for toxic effects of doxorubicin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of CycloSPORINE (Systemic). Specifically, dronabinol may displace cyclosporine from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: CycloSPORINE (Systemic) may increase the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Increase monitoring of cyclosporine concentrations when starting, stopping, or adjusting doses of concurrent efavirenz, particularly within the first 2 weeks.  Cyclosporine dose adjustment may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: CycloSPORINE (Systemic) may decrease the serum concentration of Eltrombopag. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: CycloSPORINE (Systemic) may increase the serum concentration of Eluxadoline.  Management: Decrease the eluxadoline dose to 75 mg twice daily if combined with cyclosporine and monitor patients for increased eluxadoline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide: CycloSPORINE (Systemic) may decrease the metabolism of Etoposide.  Management: Consider reducing the dose of etoposide by 50% if the patient is receiving, or has recently received, cyclosporine. Monitor for increased toxic effects of etoposide if cyclosporine is initiated, the dose is increased, or it has been recently discontinued.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide Phosphate: CycloSPORINE (Systemic) may increase the serum concentration of Etoposide Phosphate. CycloSPORINE may decrease the metabolism, via CYP isoenzymes, and decrease the p-glycoprotein-mediated elimination of Etoposide Phosphate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CycloSPORINE (Systemic) may increase the serum concentration of Everolimus.  Management: When using everolimus for renal cell carcinoma, avoid concurrent cyclosporine.  When using everolimus as post-transplant immunosuppression, concurrent cyclosporine should be used at lower doses and with lower target serum cyclosporine concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ezetimibe: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Ezetimibe.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic).  Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fimasartan: CycloSPORINE (Systemic) may increase the serum concentration of Fimasartan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Fluvastatin.  Management: Limit fluvastatin to 20 mg twice daily in patients who are also receiving cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: CycloSPORINE (Systemic) may increase the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GlyBURIDE: CycloSPORINE (Systemic) may diminish the therapeutic effect of GlyBURIDE. GlyBURIDE may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May decrease the metabolism of CycloSPORINE (Systemic). Management: Monitor for altered cyclosporine concentrations/effects if grapefruit intake is increased/decreased.  Advise patients to not alter their pattern of grapefruit/grapefruit juice intake without consulting their healthcare provider.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: CycloSPORINE (Systemic) may increase the serum concentration of Grazoprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Griseofulvin: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CycloSPORINE (Systemic) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, consider decreasing ibrutinib to 140 mg daily. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imipenem: CycloSPORINE (Systemic) may enhance the neurotoxic effect of Imipenem. Imipenem may decrease the serum concentration of CycloSPORINE (Systemic). Imipenem may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lercanidipine: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Lercanidipine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Letermovir. Management: Decrease the letermovir dose to 240 mg daily when combined with cyclosporine. Additionally, monitor for increased cyclosporine concentrations and toxicities when combined with letermovir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: CycloSPORINE (Systemic) may increase the serum concentration of Lovastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melphalan: May enhance the nephrotoxic effect of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: CycloSPORINE (Systemic) may increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of CycloSPORINE (Systemic). This may result in nephrotoxicity. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MethylPREDNISolone: CycloSPORINE (Systemic) may increase the serum concentration of MethylPREDNISolone. MethylPREDNISolone may increase the serum concentration of CycloSPORINE (Systemic). MethylPREDNISolone may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May increase the absorption of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metreleptin: May decrease the serum concentration of CycloSPORINE (Systemic). Metreleptin may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mifamurtide: CycloSPORINE (Systemic) may diminish the therapeutic effect of Mifamurtide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CycloSPORINE (Systemic). Management: Avoid cyclosporine during and 2 weeks following mifepristone for treatment of hyperglycemia in Cushing's syndrome. The interaction magnitude could be lower with single doses used to terminate pregnancy, but neither effect has been studied clinically.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minoxidil (Systemic): CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Systemic). Severe hypertrichosis has been reported. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minoxidil (Topical): CycloSPORINE (Systemic) may enhance the adverse/toxic effect of Minoxidil (Topical). Specifically, hypertrichosis risk may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MitoXANTRONE: CycloSPORINE (Systemic) may increase the serum concentration of MitoXANTRONE.  Management: Consider mitoxantrone dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution and monitor closely for toxic effects of mitoxantrone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Modafinil: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: CycloSPORINE (Systemic) may decrease the serum concentration of Mycophenolate. Specifically, cyclosporine may decrease concentrations of the active metabolite mycophenolic acid.  Management: Mycophenolate requirements may be greater in patients receiving cyclosporine. Monitor mycophenolate dosing and response to therapy particularly closely when adjusting concurrent cyclosporine (starting, stopping, or changing dose).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nafcillin: May increase the metabolism of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CycloSPORINE (Systemic) may increase the serum concentration of Neratinib.  Management: Avoid concomitant use of neratinib and cyclosporine if possible. If combined, monitor for increased neratinib effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: CycloSPORINE (Systemic) may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (eg, hypertension) during concomitant therapy with NSAIDs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Norfloxacin: May decrease the metabolism of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obeticholic Acid: BSEP/ABCB11 Inhibitors may increase serum concentrations of the active metabolite(s) of Obeticholic Acid.  Management: Avoid concomitant use of obeticholic acid and bile salt efflux pump (BSEP) inhibitors if possible. If concomitant therapy is necessary, monitor patients for elevated liver transaminases and elevated bilirubin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Reduce cyclosporine dose by 80% when initiating therapy with ombitasvir/paritaprevir/ritonavir and monitor cyclosporine blood levels closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Reduce cyclosporine dose 80% when initiating therapy with ombitasvir/paritaprevir/ritonavir/dasabuvir and monitor cyclosporine blood levels closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omeprazole: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Administer orlistat at least 3 hours before or after oral cyclosporine.  Monitor for decreased serum concentrations of oral cyclosporine, even with the recommended dose separation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May increase the metabolism of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitavastatin: CycloSPORINE (Systemic) may increase the serum concentration of Pitavastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of CycloSPORINE (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pravastatin: CycloSPORINE (Systemic) may increase the serum concentration of Pravastatin. Pravastatin may increase the serum concentration of CycloSPORINE (Systemic).  Management: Limit pravastatin to 20 mg/day in patients who are also receiving cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): May decrease the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of PrednisoLONE (Systemic). PrednisoLONE (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: CycloSPORINE (Systemic) may increase serum concentrations of the active metabolite(s) of PredniSONE. PredniSONE may decrease the serum concentration of CycloSPORINE (Systemic). PredniSONE may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Protease Inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrazinamide: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinupristin: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: CycloSPORINE (Systemic) may increase the serum concentration of Repaglinide.  Management: Limit the daily repaglinide dose to a maximum of 6 mg with concurrent use of cyclosporine, and monitor closely for increased repaglinide effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May increase the metabolism of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: CycloSPORINE (Systemic) may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Consider empiric cyclosporine dose reductions and monitor cyclosporine serum concentrations closely if ritonavir is initiated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rosuvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Rosuvastatin.  Management: Limit rosuvastatin to 5 mg/day in patients who are also receiving cyclosporine.  Canadian labeling contraindicates concomitant use of rosuvastatin with cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sevelamer: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Simeprevir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: CycloSPORINE (Systemic) may increase the serum concentration of Simvastatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: May enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described. CycloSPORINE (Systemic) may increase the serum concentration of Sirolimus. This is of specific concern with cyclosporine [MODIFIED]. Management: Administer oral doses of sirolimus 4 hours after doses of cyclosporine.  Monitor for toxic effects of sirolimus if used with cyclosporine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Somatostatin Analogs: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CycloSPORINE (Systemic). Management: Consider alternatives to St. John's wort (SJW). If the combination cannot be avoided, monitor for decreased cyclosporine concentrations/effects.  Monitor for increased cyclosporine concentrations/effects following SJW discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: May enhance the nephrotoxic effect of CycloSPORINE (Systemic). Sulfonamide Antibiotics may decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Systemic). Tacrolimus (Systemic) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Tacrolimus (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): CycloSPORINE (Systemic) may enhance the nephrotoxic effect of Tacrolimus (Topical). Tacrolimus (Topical) may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Tacrolimus (Topical) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of CycloSPORINE (Systemic). Management: Significant cyclosporine dose reductions are likely to be required if used with telaprevir. Concurrent use should be performed with great caution and close monitoring of both cyclosporine concentrations and clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: May increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: May enhance the adverse/toxic effect of CycloSPORINE (Systemic). An increased risk of calcineurin inhibitor-induced hemolytic uremic syndrome/thrombotic thrombocytopenic purpura/thrombotic microangiopathy (HUS/TTP/TMA) has been described with concomitant sirolimus use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CycloSPORINE (Systemic) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May decrease the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: OATP1B1/SLCO1B1 Inhibitors may increase the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012612\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice increases cyclosporine serum concentrations. Management: Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012556\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012557\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed following the use of oral cyclosporine in animal reproduction studies (using doses that were not maternally toxic). In humans, cyclosporine crosses the placenta; maternal concentrations do not correlate with those found in the umbilical cord. Cyclosporine may be detected in the serum of newborns for several days after birth (Claris 1993). Based on clinical use, premature births and low birth weight were consistently observed in pregnant transplant patients (additional pregnancy complications also present). Formulations may contain alcohol; the alcohol content should be taken into consideration in pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The pharmacokinetics of cyclosporine may be influenced by pregnancy (Grimer 2007). Cyclosporine may be used in pregnant renal, liver, or heart transplant patients (Cowan 2012; EBPG Expert Group on Renal Transplantation 2002; McGuire 2009; Parhar 2012). If therapy is needed for psoriasis, other agents are preferred; however, cyclosporine may be used as an alternative agent along with close clinical monitoring; use should be avoided during the first trimester if possible (Bae 2012). If treatment is needed for lupus nephritis, other agents are recommended to be used in pregnant women (Hahn 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Following transplant, normal menstruation and fertility may be restored within months; however, appropriate contraception is recommended to prevent pregnancy until 1-2 years following the transplant to improve pregnancy outcomes (Cowan 2012; EBPG Expert Group on Renal Transplantation 2002; McGuire 2009; Parhar 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16336615\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Cyclosporine is excreted in breast milk. Concentrations of cyclosporine in milk vary widely and breastfeeding during therapy is generally not recommended (Bae 2012; Cowan 2012). Due to the potential for serious adverse in the breastfeeding infant, a decision should be made to discontinue cyclosporine or to discontinue breastfeeding, taking into account the importance of treatment to the mother. Formulations may contain alcohol which may be present in breast milk and could be absorbed orally by the breastfeeding infant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012648\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit juice with oral cyclosporine use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012654\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor plasma concentrations, renal function (serum creatinine and BUN), and blood pressure periodically and following the addition, modification, or deletion of other medications. Monitor for hypersensitivity reactions (IV cyclosporine). Monitor for signs/symptoms of hepatotoxicity, secondary malignancy, diabetes mellitus, infection. Monitor for progressive cognitive or motor deficits; magnetic resonance imaging may be required for diagnosis of posterior reversible encephalopathy syndrome (PRES).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Nephrotic syndrome (Canadian labeling): Baseline blood pressure (2 readings within 2 weeks), fasting serum creatinine (at least 3 levels within 2 weeks), creatinine clearance, urinalysis, CBC, liver function, serum uric acid, serum potassium, and malignancy screening (eg, skin, mouth, lymph nodes). Biweekly monitoring of blood pressure for initial 3 months and then monthly thereafter, frequent monitoring of renal function and periodic cyclosporine trough levels are recommended during therapy. Consider renal biopsy in patients with steroid-dependent minimal change neuropathy who have been maintained on therapy &gt;1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Transplant patients: Cyclosporine trough levels, serum electrolytes, renal function, hepatic function, blood pressure, lipid profile, blood sugar, and HbA1c</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Psoriasis therapy: Baseline blood pressure, serum creatinine (2 levels each), BUN, CBC, serum magnesium, potassium, uric acid, lipid profile. Every other week monitoring of blood pressure, complete blood count, serum creatinine, and levels of BUN, uric acid, potassium, lipids, and magnesium during the first 3 months of treatment for psoriasis. Monthly monitoring is recommended after this initial period. (<b>Note: </b>The Canadian labeling recommends bimonthly monitoring of serum creatinine after the initial period if serum creatinine remains stable and cyclosporine dose is &le;2.5 mg/kg daily, and monthly monitoring for higher doses). Also evaluate any atypical skin lesions prior to therapy. Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Rheumatoid arthritis: Baseline blood pressure, and serum creatinine (2 levels each); serum creatinine every 2 weeks for first 3 months, then monthly if patient is stable. Increase the frequency of blood pressure monitoring after each alteration in dosage of cyclosporine. Additional Canadian labeling recommendations include CBC, hepatic function, urinalysis, serum potassium and uric acid (baseline and periodic thereafter).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012570\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Reference ranges are method dependent and specimen dependent; use the same analytical method consistently</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Method-dependent and specimen-dependent:</b> Trough levels should be obtained:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: 12 hours after dose or immediately prior to next dose (chronic usage)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: 12 hours after dose <b>or</b> immediately prior to next dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Therapeutic trough range in solid organ transplant (kidney, liver, heart): Not absolutely defined, dependent on organ transplanted, time after transplant, organ function and CsA toxicity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">General range of 100 to 400 ng/mL; refer to institutional protocol for specific therapeutic ranges</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Toxic level: Not well defined, nephrotoxicity may occur at any level</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Recommended cyclosporine therapeutic ranges when administered in combination with everolimus for <b>renal</b> transplant</i> (Zortress product labeling 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Month 1 post-transplant: 100 to 200 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Months 2 and 3 post-transplant: 75 to 150 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Months 4 and 5 post-transplant: 50 to 100 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Months 6 to 12 post-transplant: 25 to 50 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alternative monitoring (renal transplant):</b> Two-hour post cyclosporine dose level (obtaining a level 2 hours after administration correlates well with drug exposure throughout the 12-hour dosing interval [Schiff 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IL-2 induction therapy (2-hour post cyclosporine dose level):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Month 1 and 2: &gt;1,500 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Month 3: 1,200 to 1,400 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Month 4 to 12: 600 to 1,000 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Month &gt;12: ~800 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Antithymocyte globulin (rabbit) induction therapy (2-hour post cyclosporine dose level):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Month 1 to 3: 1,000 to 1,200 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Month 4 to 12: 600 to 1,000 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Month &gt;12: ~800 ng/mL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lung transplant (off-label use):</b> Target cyclosporine levels were maintained between 250 and 350 ng/mL during the first month, and around 200 ng/mL thereafter, depending on renal function (Zuckermann 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nephrotic syndrome (off-label use): </b>Target trough concentration (pediatrics): 80 to 100 ng/mL (Gellermann 2013). Target trough levels may vary based on protocol; point in therapy, and/or treatment goals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012568\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibition of production and release of interleukin II and inhibits interleukin II-induced activation of resting T-lymphocytes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012571\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (non-modified): Erratic and incomplete; dependent on presence of food, bile acids, and GI motility; larger oral doses are needed in pediatrics due to shorter bowel length and limited intestinal absorption</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (modified): Erratic and incomplete; increased absorption, up to 30% when compared to cyclosporine (non-modified); less dependent on food, bile acids, or GI motility when compared to cyclosporine (non-modified)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely in tissues and body fluids including the liver, pancreas, and lungs</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>dss</sub>: 4-6 L/kg in renal, liver, and marrow transplant recipients (slightly lower values in cardiac transplant patients; children &lt;10 years have higher values); ESRD: 3.49 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 90% to 98% to lipoproteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via CYP3A4; forms at least 25 metabolites; extensive first-pass effect following oral administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (non-modified): Dependent on patient population and transplant type (&lt;10% in adult liver transplant patients and as high as 89% in renal transplant patients); bioavailability of Sandimmune capsules and oral solution are equivalent; bioavailability of oral solution is ~30% of the IV solution</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children: 28% (range: 17% to 42%); gut dysfunction common in BMT patients and oral bioavailability is further reduced</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (modified): Bioavailability of Neoral capsules and oral solution are equivalent:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children: 43% (range: 30% to 68%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 23% greater than with cyclosporine (non-modified) in renal transplant patients; 50% greater in liver transplant patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Oral: May be prolonged in patients with hepatic impairment and shorter in pediatric patients due to the higher metabolism rate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (non-modified): Biphasic: Alpha: 1.4 hours; Terminal: 19 hours (range: 10-27 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (modified): Biphasic: Terminal: 8.4 hours (range: 5-18 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (non-modified): 2-6 hours; some patients have a second peak at 5-6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cyclosporine (modified): Renal transplant: 1.5-2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily feces; urine (6%, 0.1% as unchanged drug and metabolites); clearance is more rapid in pediatric patients than in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012694\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (CycloSPORINE Modified Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $41.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $82.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $164.89</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (CycloSPORINE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $99.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $335.15</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Gengraf Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (30): $63.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (30): $126.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (30): $251.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Neoral Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $2.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $9.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (SandIMMUNE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (1): $4.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $16.91</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CycloSPORINE Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (5 mL): $46.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (CycloSPORINE Modified Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (50 mL): $299.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Gengraf Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (50 mL): $474.38</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neoral Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (50 mL): $536.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SandIMMUNE Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (5 mL): $65.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SandIMMUNE Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/mL (50 mL): $820.09</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961966\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arpimune (PH);</li>\n      <li>Biosporin (EC);</li>\n      <li>Capimune (GB);</li>\n      <li>Cermox (AR);</li>\n      <li>Ciclohexal (ZA);</li>\n      <li>Cicloral (AU, DE);</li>\n      <li>Cipol (KR);</li>\n      <li>Cipol-N (KR);</li>\n      <li>Ciqorin (ES);</li>\n      <li>Cloperin (BD);</li>\n      <li>Consupren (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Cyclonix (BD);</li>\n      <li>Cyclorine (JO);</li>\n      <li>Cyrin (PH);</li>\n      <li>Deximune (GB, IL, MT, SG);</li>\n      <li>Equoral (AE, EE, HR, LT, RO, TH);</li>\n      <li>Gengraf (AE, HK, MY, QA, SA, VN);</li>\n      <li>Ikervis (IE);</li>\n      <li>Implanta (KR);</li>\n      <li>Imusporin (CO, IN);</li>\n      <li>Imusporyn (UA);</li>\n      <li>Kasporin (TH);</li>\n      <li>Neoral (FR, GB, IE, JP, NZ, TW);</li>\n      <li>Osporin (PH);</li>\n      <li>Promune (LK);</li>\n      <li>Sandimmum Neoral (ES);</li>\n      <li>Sandimmun (AT, AU, BE, BF, BJ, CH, CI, CL, CZ, DE, DK, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, ID, IE, IL, IS, IT, JP, KE, KR, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NO, NZ, PE, PH, PK, PL, PT, RU, SC, SD, SE, SI, SK, SL, SN, TN, TR, TW, TZ, UG, UY, VE, ZM, ZW);</li>\n      <li>Sandimmun Neoral (AE, AR, AT, AU, BH, BR, CH, CL, CU, CY, CZ, EE, EG, FI, GB, GR, HK, HR, ID, IL, IQ, IR, IS, JO, KR, KW, LB, LK, LT, LV, LY, MT, MY, NO, OM, PE, PH, PL, PY, QA, RO, SA, SE, SI, SK, SY, TH, TR, UA, UY, VE, VN, YE, ZA);</li>\n      <li>Sandimmune (BB, NL);</li>\n      <li>Sigamsporin (AE);</li>\n      <li>Sigmasporin (KW, QA);</li>\n      <li>Sporium (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Andrews DJ and Cramb R, &ldquo;Cyclosporin: Revisions in Monitoring Guidelines and Review of Current Analytical Methods,&rdquo; <i>Ann Clin Biochem</i>, 2002, 39(Pt 5):424-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/12227848/pubmed\" target=\"_blank\" id=\"12227848\">12227848</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007;116.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al. National Psoriasis Foundation. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. <i>J Am Acad Dermatol</i>. 2012;67(3):459-477.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/22018758/pubmed\" target=\"_blank\" id=\"22018758\">22018758</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benfield MR, Tejani A, Harmon WE, et al, &ldquo;A Randomized Multicenter Trial of OKT3 mAbs Induction Compared With Intravenous Cyclosporine in Pediatric Renal Transplantation,&rdquo; <i>Pediatr Transplant</i>, 2005, 9(3):282-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/15910382/pubmed\" target=\"_blank\" id=\"15910382\">15910382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boni R and Dummer R, &ldquo;Abscessed Inflammation as a Serious Complication of Low Dose Cyclosporin A in Atopic Dermatitis,&rdquo; <i>Eur J Dermatol</i>, 1995, 5:268-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18646090\"></a>Braun N, Schmutzler F, Lange C, et al, &ldquo;Immunosuppressive Treatment for Focal Segmental Glomerulosclerosis in Adults,&rdquo; <i>Cochrane Database Syst Rev</i>, 2008, (3):CD003233.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/18646090/pubmed\" target=\"_blank\" id=\"18646090\">18646090</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caforio AL, Gambino A, Tona F, &ldquo;Sulfinpyrazone Reduces Cyclosporine Levels: A New Drug Interaction in Heart Transplant Recipients,&rdquo; <i>J Heart Lung Transplant</i>, 2000, 19(12):1205-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/11124491/pubmed\" target=\"_blank\" id=\"11124491\">11124491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10594798\"></a>Cattran DC, Appel GB, Hebert LA, et al, &ldquo;A Randomized Trial of Cyclosporine in Patients With Steroid-Resistant Focal Segmental Glomerulosclerosis. North America Nephrotic Syndrome Study Group,&rdquo; <i>Kidney Int</i>, 1999, 56(6):2220-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/10594798/pubmed\" target=\"_blank\" id=\"10594798\">10594798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8413388\"></a>Chao NJ, Schmidt GM, Niland JC, et al, &ldquo;Cyclosporine, Methotrexate, and Prednisone Compared with Cyclosporine and Prednisone for Prophylaxis of Acute Graft-Versus-Host Disease,&rdquo; <i>N Engl J Med</i>, 1993, 329(17):1225-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/8413388/pubmed\" target=\"_blank\" id=\"8413388\">8413388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10871150\"></a>Chao NJ, Snyder DS, Jain M, et al, &ldquo;Equivalence of 2 Effective Graft-Versus-Host Disease Prophylaxis Regimens: Results of a Prospective Double-Blind Randomized Trial,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2000, 6(3):254-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/10871150/pubmed\" target=\"_blank\" id=\"10871150\">10871150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choudhary DR, Naithani R, Mahapatra M, Kumar R, Mishra P, Saxena R. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. <i>Haematologica</i>. 2008;93(10):e61-e62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/18827257/pubmed\" target=\"_blank\" id=\"18827257\">18827257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Claris O, Picaud JC, Brazier JL, et al, &quot;Pharmacokinetics of Cyclosporin A in 16 Newborn Infants of Renal or Cardiac Transplant Mothers,&quot; <i>Dev Pharmacol Ther</i>, 1993, 20(3-4):180-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7828451/pubmed\" target=\"_blank\" id=\"7828451\">7828451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cowan SW, Davison JM, Doria C, et al. Pregnancy after cardiac transplantation. <i>Cardiol Clin</i>. 2012;30(3):441-452.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/22813369/pubmed\" target=\"_blank\" id=\"22813369\">22813369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies MG and Bowers PW, &ldquo;Alopecia Areata Arising in Patients Receiving Cyclosporin Immunosuppression,&rdquo; <i>Br J Dermatol</i>, 1995, 132(5):835-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7772501/pubmed\" target=\"_blank\" id=\"7772501\">7772501</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16091057\"></a>De Saussure P, Soravia C, Morel P, et al, &ldquo;Low-Dose Oral Microemulsion Ciclosporin for Severe, Refractory Ulcerative Colitis,&rdquo; <i>Aliment Pharmacol Ther</i>, 2005, 22(3):203-08.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/16091057/pubmed\" target=\"_blank\" id=\"16091057\">16091057</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D&iacute;az-Llopis M, Gallego-Pinazo R, Garc&iacute;a-Delpech S, Salom-Alonso D. General principles for the treatment of non-infectious uveitis. <i>Inflamm Allergy Drug Targets</i>. 2009;8(4):260-265.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/19754409/pubmed\" target=\"_blank\" id=\"19754409\">19754409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ducharme MP, Warbasse LH, and Edwards DJ, &ldquo;Disposition of Intravenous and Oral Cyclosporine After Administration With Grapefruit Juice,&rdquo; <i>Clin Pharmacol Ther</i>, 1995, 57(5):485-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7768070/pubmed\" target=\"_blank\" id=\"7768070\">7768070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunn CJ, Wagstaff AJ, Perry CM, et al, &quot;Cyclosporin: An Updated Review of the Pharmacokinetic Properties, Clinical Efficacy and Tolerability of a Microemulsion-Based Formulation (Neoral) 1 in Organ Transplantation,&quot; <i>Drugs</i>, 2001, 61(13):1957-2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/11708766/pubmed\" target=\"_blank\" id=\"11708766\">11708766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. <i>Nephrol Dial Transplant</i>. 2002;(17 Suppl 4):50-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/12091650/pubmed\" target=\"_blank\" id=\"12091650\">12091650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emilia G, Morselli M, Luppi M, et al. Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. <i>Blood</i>. 2002;99(4):1482-1485.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/11830504/pubmed\" target=\"_blank\" id=\"11830504\">11830504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. <i>J Urol</i>. 2012;188(4):1186-1191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/22901569/pubmed\" target=\"_blank\" id=\"22901569\">22901569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23813218\"></a>Gellermann J, Weber L, Pape L, et al. Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. <i>J Am Soc Nephrol</i>. 2013;24(10):1689-1697.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/23813218/pubmed\" target=\"_blank\" id=\"23813218\">23813218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gengraf (cyclosporine) capsules [prescribing information]. North Chicago, IL: AbbVie Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gengraf (cyclosporine) oral solution [prescribing information]. North Chicago, IL: AbbVie Inc; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grimer M; Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Calcineurin inhibitors in renal transplantation: pregnancy, lactation and calcineurin inhibitors. <i>Nephrology (Carlton)</i>. 2007;(12 Suppl 1):S98-S105.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/17316288/pubmed\" target=\"_blank\" id=\"17316288\">17316288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahn BH, McMahon MA, Wilkinson A, et al, &quot;American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(6):797-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/22556106/pubmed\" target=\"_blank\" id=\"22556106\">22556106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Higgins EM, Hughes JR, Snowden S, et al, &ldquo;Cyclosporin-Induced Periungual Granulation Tissue,&rdquo; <i>Br J Dermatol</i>, 1995, 132(5):829-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7772496/pubmed\" target=\"_blank\" id=\"7772496\">7772496</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollander AA, van Rooij J, Lentjes GW, et al, &ldquo;The Effect of Grapefruit Juice on Cyclosporine and Prednisone Metabolism in Transplant Patients,&rdquo; <i>Clin Pharmacol Ther</i>, 1995, 57(3):318-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7697949/pubmed\" target=\"_blank\" id=\"7697949\">7697949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holt DW, Mueller EA, Kovarik JM, et al, &ldquo;Sandimmune Neoral Pharmacokinetics: Impact of the New Oral Formulation,&rdquo; <i>Transplant Proc</i>, 1995, 27(1):1434-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7878935/pubmed\" target=\"_blank\" id=\"7878935\">7878935</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Honcharik N and Anthone S, &ldquo;Activated Charcoal in Acute Cyclosporine Overdose,&rdquo; <i>Lancet</i>, 1985, 1(8436):1051.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horton RC and Bonser RS, &ldquo;Interaction Between Cyclosporin and Fluoxetine,&rdquo; <i>BMJ</i>, 1995, 311(7002):422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7640589/pubmed\" target=\"_blank\" id=\"7640589\">7640589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes RL, &ldquo;Cyclosporine-Related Central Nervous System Toxicity in Cardiac Transplantation,&rdquo; <i>N Engl J Med</i>, 1990, 323(6):420-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/2370897/pubmed\" target=\"_blank\" id=\"2370897\">2370897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Inamoto Y, Flowers ME, Appelbaum FR, et al, &ldquo;A Retrospective Comparison of Tacrolimus versus Cyclosporine With Methotrexate for Immunosuppression After Allogeneic Hematopoietic Cell Transplantation With Mobilized Blood Cells,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2011, 17(7):1088-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/21421070/pubmed\" target=\"_blank\" id=\"21421070\">21421070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients:follow-up study. <i>J Am Soc Nephrol</i>. 2002;13(12):2962-2968.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/12444215/pubmed\" target=\"_blank\" id=\"12444215\">12444215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kabeer MH, Filo RS, Milgrom ML, et al, &ldquo;Central Pontine Myelinolysis Following Orthotopic Liver Transplant: Association With Cyclosporine Toxicity,&rdquo; <i>Postgrad Med J</i>, 1995, 71(834):239-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7784287/pubmed\" target=\"_blank\" id=\"7784287\">7784287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaufman DB, Kaplan B, Kanwar YS, et al, &ldquo;The Successful Use of Tacrolimus (FK506) in a Pancreas/Kidney Transplant Recipient With Recurrent Cyclosporine-Associated Hemolytic Uremic Syndrome,&rdquo; <i>Transplantation</i>, 1995, 59(12):1737-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7541579/pubmed\" target=\"_blank\" id=\"7541579\">7541579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"KDIGO.2012\"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. <i>Kidney Int. Suppl.</i> 2012;139-274.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kino KJ and Wittkowsky AK, &ldquo;Influence of Bile Acid Replacement on Cyclosporine Absorption in a Patient With Jejunoileal Bypass,&rdquo; <i>Pharmacotherapy</i>, 1995, 15(3):350-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7667169/pubmed\" target=\"_blank\" id=\"7667169\">7667169</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kornbluth A and Sachar DB, &ldquo;Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee,&rdquo; <i>Am J Gastroenterol</i>, 2010, 105(3):501-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/20068560/pubmed\" target=\"_blank\" id=\"20068560\">20068560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19450759\"></a>Lanino E, Rondelli R, Locatelli F, et al. Early (day -7) versus conventional (day -1) inception of cyclosporine-A for graft-versus-host disease prophylaxis after unrelated donor hematopoietic stem cell transplantation in children. Long-term results of an AIEOP prospective, randomized study. <i>Biol Blood Marrow Transplant</i>. 2009;15(6):741-748.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/19450759/pubmed\" target=\"_blank\" id=\"19450759\">19450759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo; <i>Am J Gastroenterol</i>, 2009, 104(2):465-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/19174807/pubmed\" target=\"_blank\" id=\"19174807\">19174807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8196726\"></a>Lichtiger S, Present DH, Kornbluth A, et al, &ldquo;Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, <i>N Engl J Med</i>, 1994, 330(26):1841-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/8196726/pubmed\" target=\"_blank\" id=\"8196726\">8196726</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin CY and Lee SF, &ldquo;Comparison of Pharmacokinetics Between CsA Capsules and Sandimmune&reg; Neoral&reg; in Pediatric Patients,&rdquo; <i>Transplant Proc</i>, 1994, 26(5):2973-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7940938/pubmed\" target=\"_blank\" id=\"7940938\">7940938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14561988\"></a>Martin P, Bleyzac N, Souillet G, et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. <i>Bone Marrow Transplant</i>. 2003;32(9):881-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/14561988/pubmed\" target=\"_blank\" id=\"14561988\">14561988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. <i>Indian J Ophthalmol</i>. 2010;58(1):55-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/20029146/pubmed\" target=\"_blank\" id=\"20029146\">20029146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGuire BM, Rosenthal P, Brown CC, et al; American Society of Transplantation. Long-term management of the liver transplant patient: recommendations for the primary care doctor. <i>Am J Transplant</i>. 2009;9(9):1988-2003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/19563332/pubmed\" target=\"_blank\" id=\"19563332\">19563332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McIntyre HD, Menzies B, Rigby R, et al, &ldquo;Long-Term Bone Loss After Renal Transplantation: Comparison of Immunosuppressive Regimens,&rdquo; <i>Clin Transplant</i>, 1995, 9(1):20-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7742578/pubmed\" target=\"_blank\" id=\"7742578\">7742578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Memon M, de Magalhace-Silverman M, Bloom EJ, et al, &ldquo;Reversible Cyclosporine-Induced Cortical Blindness in Allogeneic Bone Marrow Transplant Recipients,&rdquo; <i>Bone Marrow Transplant</i>, 1995, 15(2):283-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7773219/pubmed\" target=\"_blank\" id=\"7773219\">7773219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19493586\"></a>Menter A, Korman NJ, Elmets CA, et al. Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 4. Guidelines of Care for the Management and Treatment of Psoriasis With Traditional Systemic Agents. <i>J Am Acad Dermatol</i>, 2009, 61(3):451-485.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/19493586/pubmed\" target=\"_blank\" id=\"19493586\">19493586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17699309\"></a>Moroni G, Doria A, Mosca M, et al, &ldquo;A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis Over Four Years,&rdquo; <i>Clin J Am Soc Nephrol</i>, 2006, 1(5):925-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/17699309/pubmed\" target=\"_blank\" id=\"17699309\">17699309</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. <i>Arch Ophthalmol</i>. 2005;123(5):634-641.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/15883282/pubmed\" target=\"_blank\" id=\"15883282\">15883282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10979948\"></a>Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine forprophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. <i>Blood</i>. 2000;96(6):2062-2068.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/10979948/pubmed\" target=\"_blank\" id=\"10979948\">10979948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neoral (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neoral (cyclosporine) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Niese D, &ldquo;A Double-Blind Randomized Study of Sandimmune Neoral vs Sandimmune in New Renal Transplant Recipients: Results After 12 Months,&rdquo; <i>Transplant Proc</i>, 1995, 27(2):1849-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7725531/pubmed\" target=\"_blank\" id=\"7725531\">7725531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17437162\"></a>Ogawa H, Kameda H, Nagasawa H, et al, Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis, <i>Mod Rheumatol</i>, 2007;17(2):92-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/17437162/pubmed\" target=\"_blank\" id=\"17437162\">17437162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozdal PC, Orta&ccedil; S, Taskintuna I, Firat E. Long-term therapy with low dose cyclosporin A in ocular Beh&ccedil;et's disease. <i>Doc Ophthalmol</i>. 2002;105(3):301-312.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/12539855/pubmed\" target=\"_blank\" id=\"12539855\">12539855</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, Ruscin JM, Fish D, et al, &quot;Possible Interaction Between Intravenous Azithromycin and Oral Cyclosporine,&quot; <i>Pharmacotherapy</i>, 2001, 21(11):1436-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/11714218/pubmed\" target=\"_blank\" id=\"11714218\">11714218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parhar KS, Gibson PS, Coffin CS. Pregnancy following liver transplantation: review of outcomes and recommendations for management. <i>Can J Gastroenterol</i>. 2012;26(9):621-626.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/22993734/pubmed\" target=\"_blank\" id=\"22993734\">22993734</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Passfall J, Schuller I, and Keller F, &ldquo;Pharmacokinetics of Cyclosporin During Administration of Danazol,&rdquo; <i>Nephrol Dial Transplant</i>, 1994, 9(12):1807-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7708271/pubmed\" target=\"_blank\" id=\"7708271\">7708271</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23728681\"></a>Penninga L, Penninga EI, Moller CH, Iversen M, Steinbruchel DA, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. <i>Cochrane Database Syst Rev</i>. 2013;31(5):CD008817.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/23728681/pubmed\" target=\"_blank\" id=\"23728681\">23728681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pollard S, Nashan B, Johnston A, et al, &quot;A Pharmacokinetic and Clinical Review of the Potential Clinical Impact of Using Different Formulations of Cyclosporin A. Berlin, Germany, November 19, 2001,&quot; <i>Clin Ther</i>, 2003, 25(6): 1654-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/12860490/pubmed\" target=\"_blank\" id=\"12860490\">12860490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i>. 2010;115(2):168-186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/19846889/pubmed\" target=\"_blank\" id=\"19846889\">19846889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9746768\"></a>Ratanatharathorn V, Nash RA, Przepiorka D, et al, &quot;Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation,&quot; <i>Blood</i>, 1998, 92(7):2303-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/9746768/pubmed\" target=\"_blank\" id=\"9746768\">9746768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10534058\"></a>Ross M, Schmidt GM, Niland JC, et al, &ldquo;Cyclosporine, Methotrexate, and Prednisone Compared With Cyclosporine and Prednisone for Prevention of Acute Graft-vs.-Host Disease: Effect on Chronic Graft-vs.-Host Disease and Long-Term Survival,&rdquo; <i>Biol Blood Marrow Transplant</i>, 1999, 5(5):285-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/10534058/pubmed\" target=\"_blank\" id=\"10534058\">10534058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23892326\"></a>Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplant. </i>2014;49(2):168-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/23892326/pubmed\" target=\"_blank\" id=\"23892326\">23892326</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. <i>J Urol</i>. 2004;171(6 pt 1):2138-2141.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/15126772/pubmed\" target=\"_blank\" id=\"15126772\">15126772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sairanen J, Hotakainen K, Tammela TL, Stenman UH, Ruutu M. Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium. <i>Urology</i>. 2008;71(4):630-633.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/18387391/pubmed\" target=\"_blank\" id=\"18387391\">18387391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. <i>J Urol</i>. 2005;174(6):2235-2238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/16280777/pubmed\" target=\"_blank\" id=\"16280777\">16280777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandimmune (cyclosporine) [prescribing information]. East Hanover, NJ: Novartis; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandimmune (cyclosporine) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scalzini A, Barni C, Stellini R, et al, &ldquo;Fatal Invasive Aspergillosis During Cyclosporine and Steroids Treatment for Crohn's Disease,&rdquo; <i>Dig Dis Sci</i>, 1995, 40(3):528.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7895537/pubmed\" target=\"_blank\" id=\"7895537\">7895537</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17699437\"></a>Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. <i>Clin J Am Soc Nephrol</i>. 2007;2(2):374-384.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/17699437/pubmed\" target=\"_blank\" id=\"17699437\">17699437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sharma RK, Kumar P, Rai P, et al, &ldquo;Cyclosporine Neurotoxicity in a Renal-Transplant Recipient,&rdquo; <i>Nephron</i>, 1995, 70(2):269.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7566320/pubmed\" target=\"_blank\" id=\"7566320\">7566320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3521761\"></a>Storb R, Deeg HJ, Farewell V, et al, &ldquo;Marrow Transplantation for Severe Aplastic Anemia: Methotrexate Alone Compared With a Combination of Methotrexate and Cyclosporine for Prevention of Acute Graft-Versus-Host Disease,&rdquo; <i>Blood</i>, 1986, 68(1):119-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/3521761/pubmed\" target=\"_blank\" id=\"3521761\">3521761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3513012\"></a>Storb R, Deeg HJ, Whitehead J, et al, &ldquo;Methotrexate and Cyclosporine Compared With Cyclosporine Alone for Prophylaxis of Acute Graft Versus Host Disease After Marrow Transplantation for Leukemia,&rdquo; <i>N Engl J Med</i>, 1986, 314(12):729-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/3513012/pubmed\" target=\"_blank\" id=\"3513012\">3513012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taesch S, Niese D, and Mueller EA, &ldquo;Sandimmune&reg; Neoral&reg;, A New Oral Formulation of Cyclosporine With Improved Pharmacokinetic Characteristics: Safety and Tolerability in Renal Transplant Patients,&rdquo; <i>Transplant Proc</i>, 1994, 26(6):3147-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7998097/pubmed\" target=\"_blank\" id=\"7998097\">7998097</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ten Tije AJ, Verweij J, Loos WJ, et al. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. <i>Clin Pharmacokinet</i>. 2003;42(7):665-685.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/12844327/pubmed\" target=\"_blank\" id=\"12844327\">12844327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tugwell P, Pincus T, Yocum D, et al, &ldquo;Combination Therapy With Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis,&rdquo; <i>N Engl J Med</i>, 1995, 333(3):137-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/7791814/pubmed\" target=\"_blank\" id=\"7791814\">7791814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14517785\"></a>Van Assche G, D&rsquo;Haens G, Noman M, et al, &ldquo;Randomized, Double-Blind Comparison of 4 mg/kg Versus 2 mg/kg Intravenous Cyclosporine in Severe Ulcerative Colitis,&rdquo; <i>Gastroenterology</i>, 2003, 125(4):1025-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/14517785/pubmed\" target=\"_blank\" id=\"14517785\">14517785</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wandstrat TL, Schroeder TJ, and Myre SA, &ldquo;Cyclosporine Pharmacokinetics in Pediatric Transplant Recipients,&rdquo; <i>Ther Drug Monit</i>, 1989, 11(5):493-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/2683250/pubmed\" target=\"_blank\" id=\"2683250\">2683250</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17119387\"></a>Weber A, Fein F, Koch S, et al, &ldquo;Treatment of Ulcerative Colitis Refractory to Steroid Therapy by Oral Microemulsion Cyclosporin (Neoral),&rdquo; <i>Inflamm Bowel Dis</i>, 2006, 12(12):1131-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/17119387/pubmed\" target=\"_blank\" id=\"17119387\">17119387</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wells G and Tugwell P, &ldquo;Cyclosporin A in Rheumatoid Arthritis: Overview of Efficacy,&rdquo; <i>Br J Rheumatol</i>, 1993, 32(Suppl 1):51-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/8448639/pubmed\" target=\"_blank\" id=\"8448639\">8448639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20685255\"></a>Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. <i>Biol Blood Marrow Transplant.</i> 2011;17(1):1-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/20685255/pubmed\" target=\"_blank\" id=\"20685255\">20685255</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaghetto JM, Yamamoto MM, Souza MB, et al. Chlorambucil and cyclosporine A in Brazilian patients with Beh&ccedil;et's disease uveitis: a retrospective study. <i>Arq Bras Oftalmol</i>. 2010;73(1):40-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/20464112/pubmed\" target=\"_blank\" id=\"20464112\">20464112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zortress (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Co; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12698153\"></a>Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial. <i>J Thorac Cardiovasc Surg</i>. 2003;125(4):891-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/12698153/pubmed\" target=\"_blank\" id=\"12698153\">12698153</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zver S, Zupan IP, Cernelc P. Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure. <i>Int J Hematol</i>. 2006;83(3):238-242.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-systemic-drug-information/abstract-text/16720554/pubmed\" target=\"_blank\" id=\"16720554\">16720554</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9094 Version 240.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8012536\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8012539\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8012540\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8015573\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8012583\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8012582\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8012644\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8012645\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8012646\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8012692\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8012552\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21664250\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F23294978\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8012649\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130962\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8012553\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475238\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8012538\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8012602\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8012561\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8012600\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8012607\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8012608\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8012612\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8012556\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8012557\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16336615\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8012648\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8012654\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F8012570\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8012568\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8012571\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8012694\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961966\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9094|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-patient-drug-information\" class=\"drug drug_patient\">Cyclosporine (ciclosporin) (systemic): Patient drug information \t</a></li><li><a href=\"topic.htm?path=cyclosporine-ciclosporin-systemic-pediatric-drug-information\" class=\"drug drug_pediatric\">Cyclosporine (ciclosporin) (systemic): Pediatric drug information</a></li></ul></div></div>","javascript":null}